This implies that the biomarker potential of tmTNFα and TNFR2 for lung cancer progression most likely pivots on the delicate balances of sTNFα over tmTNFα as well as TNFR1 over TNFR2. This evidence concerns the gene TNFRSF1A and lung cancer.